Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an a...

Full description

Bibliographic Details
Main Authors: Momtchilo Russo, Maria Cássia Mendes-Corrêa, Bruna B. Lins, Victor Kersten, Paulo C. A. Pernambuco Filho, Toni Ricardo Martins, Tânia Regina Tozetto-Mendoza, Lucy Santos Vilas Boas, Brisa Moreira Gomes, Livia Mendonça Munhoz Dati, Amaro Nunes Duarte-Neto, Gustavo Roncoli Reigado, Ana Beatriz T. Frederico, Danielle R. de A. de Brito e Cunha, Anderson Vicente de Paula, José Igor G. da Silva, Carlos F. Moreira Vasconcelos, Felipe S. Chambergo, Viviane Abreu Nunes, Ana Paula Dinis Ano Bom, Leda R. Castilho, Rodrigo A. P. Martins, Mario Hiroyuki Hirata, Luciana Mirotti
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Vaccines
Subjects:
SARS-CoV-2
vaccine
hACE2 transgenic mice
intranasal route
spike protein
cationic liposome
Online Access:https://www.mdpi.com/2076-393X/11/11/1732

Internet

https://www.mdpi.com/2076-393X/11/11/1732

Similar Items